迪安诊断(300244) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥2,973,005,617.76, a decrease of 8.01% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥23,170,466.54, down 85.54% year-over-year[5]. - The net profit after deducting non-recurring gains and losses was ¥23,536,277.50, representing an 83.01% decline from the previous year[5]. - The net profit for the current period is 76,393,132.63, a decrease from 254,851,363.05 in the previous period, representing a decline of approximately 70%[29]. - The total profit for the current period is 101,365,629.84, down from 355,241,974.73, indicating a decrease of about 71%[29]. - The operating profit for the current period is 102,858,253.38, compared to 360,492,005.57 in the previous period, reflecting a decline of approximately 71%[29]. - Basic earnings per share for the current period is 0.0371, down from 0.2557 in the previous period, indicating a decrease of approximately 85%[30]. - The total comprehensive income attributable to the parent company is 23,169,898.96, a significant drop from 160,273,989.61 in the previous period, representing a decline of about 86%[30]. - The total comprehensive income attributable to minority shareholders is 53,222,666.09, compared to 94,577,373.44 in the previous period, indicating a decrease of approximately 44%[30]. Cash Flow and Liquidity - The cash flow from operating activities was -¥266,945,833.56, a 16.71% increase in negative cash flow compared to last year[5]. - The cash flow from operating activities shows a net outflow of 266,945,833.56, compared to a net outflow of 228,725,675.95 in the previous period[30]. - The cash flow from investing activities resulted in a net outflow of 459,639,091.92, compared to a net outflow of 75,059,602.72 in the previous period[31]. - The cash flow from financing activities generated a net inflow of 35,668,498.90, contrasting with a net outflow of 301,079,035.95 in the previous period[31]. - Cash and cash equivalents decreased to CNY 2.27 billion from CNY 2.97 billion, reflecting a reduction in liquidity[24]. - Cash and cash equivalents at the end of the period amount to 2,256,555,242.50, down from 3,540,080,774.49 at the end of the previous period[31]. - Cash and cash equivalents at the end of Q1 2024 were not specified but are critical for assessing liquidity[48]. Assets and Liabilities - Total assets at the end of the reporting period were ¥17,855,213,090.08, a decrease of 0.47% from the end of the previous year[5]. - The company's total assets amounted to CNY 17,855,213,090.08, a slight decrease from CNY 17,939,311,256.63 at the end of the previous quarter[44]. - Total liabilities decreased to CNY 7,945,903,437.23 from CNY 8,034,531,783.60, indicating a reduction of 1.11%[44]. - Long-term receivables decreased by 38.98% to CNY 15.65 million due to the recovery of matured receivables[17]. - Long-term equity investments increased by 46.26% to CNY 980.51 million, primarily due to the acquisition of equity in an associate[17]. - The equity attributable to shareholders of the parent company was CNY 7,497,593,403.99, down from CNY 7,566,265,438.86[45]. Operational Highlights - The diagnostic services business generated revenue of ¥1,149,000,000, a decrease of 5.97% year-over-year, while ICL revenue was ¥1,071,000,000, showing a growth of 10.41%[8]. - The company is focusing on cost reduction and efficiency improvement through supply chain optimization and strategic business deepening[8]. - The company is increasing R&D investment in key disease areas and business model solutions, particularly in LDT, IVD, and digital intelligence[8]. - The company is accelerating its international business expansion to tap into overseas markets for its products and services[8]. - Research and development expenses decreased to CNY 72,330,627.47 in Q1 2024 from CNY 99,924,701.55 in Q1 2023, reflecting a reduction of 27.77%[45]. Shareholder Actions - The company repurchased 5,032,500 shares, accounting for 0.80% of the total share capital, with a total transaction amount of CNY 91.32 million[23]. - The company plans to use between CNY 100 million and CNY 200 million for share repurchase to implement employee stock ownership plans or equity incentives[23].